- Research article
- Open Access
Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus
© Arcenas and Widen; licensee BioMed Central Ltd. 2002
- Received: 13 March 2002
- Accepted: 23 July 2002
- Published: 23 July 2002
Studies examining herpesvirus-herpesvirus (cytomegalovirus (CMV)-Epstein-Barr virus (EBV)) interactions are limited, and many of the studies have been clinical observations suggesting such an interaction exists. This report aims to examine the in vitro susceptibilities of BJAB-B1 and P3HR-1 cells (EBV positive Burkitt's lymphoma B-cell lines) to a CMV superinfection; and show that EBV reactivation occurs after CMV superinfects these cell lines.
The BJAB-B1 and P3HR-1 cells were observed to be susceptible to a CMV superinfection by the detection of the major immediate early (MIE) viral transcript and protein (p52) expression. The BZLF1 transcript was observed in both cell lines superinfected with CMV, indicating EBV reactivation. BZLF1 protein was observed in the BJAB-B1 cells. Antigen detection was not performed in the P3HR-1 cells.
The results from the in vitro superinfections support the in vivo studies suggesting a CMV infection is related to an EBV reactivation and suggests that CMV may be important as a co-factor in EBV pathogenesis in the immunocompromised patient.
- Abortive Infection
- Major Immediate Early
- BZLF1 Gene
- Shell Vial Assay
- BZLF1 Protein
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), in immunocompetent individuals, are etiologically associated with infectious mononucleosis as well as other disease presentations and malignancies [1, 2]. Once a person has recovered from an active herpesvirus infection, it will establish a latent infection. Maintenance of viral latency is primarily determined by the immune status of the host; but there are other factors that can contribute to herpesviral reactivation [3–7].
There are numerous studies observing CMV and EBV reactivation in immunosuppressed patients. CMV is the most important pathogen among these patients and the virus can cause both direct and indirect effects [8–13]. Among solid organ transplant recipients, the effects of CMV disease are similar among all patients, with the exception being the effect on the transplanted organ [10, 14–17]. The most common disease presentation of CMV in AIDS patients is retinitis [8, 11]. The significance of CMV disease in transplant and HIV infected individuals goes much further than the direct pathological effects because CMV has been shown to be an immune modulator and may contribute significantly to the net immunosuppressive status of the patient . This immunomodulation would therefore increase the susceptibility to superinfections from other pathogens.
Oral hairy leukoplakia, caused by EBV, can be present in 25% of HIV infected individuals [8, 18]. Other clinical presentations have been observed as well [8, 19, 20]. Birx et al. observed that patients with AIDS or AIDS-related disorders have a defect in the regulation of EBV infected B-cells and these patients have high circulating numbers of these infected cells . Post-transplant lymphoproliferative disorder (PTLD) results from the uncontrolled lymphoproliferation of EBV infected B-cells in transplant patients [22, 23]. There are many known factors for the development of PTLD, among which is the presence of an active CMV infection [13, 19, 22–24].
Many studies have focused upon the presence of a single herpesvirus in the transplant or AIDS patient [8–10]. There are fewer studies examining virus-virus interactions and the effect they may have on each other. Although several investigators have focused upon the relationship of human herpesvirus-6 (HHV-6) (same herpesvirus subfamily as CMV) and HIV [25–29], studies dealing with potential herpesvirus-herpesvirus interactions are very limited. Such studies would be interesting since CMV infection has been suggested as a risk factor for the development of PTLD [22, 24]. Investigators have showed that a large percentage of transplant patients who had developed PTLD also had CMV disease [22, 30]. In addition to CMV being implicated as a factor for the development of PTLD, serological studies have shown that patients with an active CMV infection experienced a serological profile of EBV reactivation [22, 31, 32]. Cross reactivities between the two viruses were ruled out as a cause for the observed immunoreactivations.
One study performed in vitro superinfections of EBV positive cell lines (Akata, Raji, and P3HR-1) with HHV-6. EBV reactivation was observed to occur in those cell lines that were superinfected with HHV-6 and the authors hypothesized that there was a direct effect of HHV-6 on EBV reactivation . A more recent study by Vieira et al. was able to show human herpesvirus-8 (HHV-8) activation of lytic replication by CMV . HHV-8 is in the same herpesvirus subfamily as EBV. The clinical studies do suggest that there may be a relationship between CMV infection and EBV reactivation, and the in vitro studies strengthen the notion of potential herpesvirus-herpesvirus interactions occurring. However, the effect CMV and EBV may have on each other has not specifically been investigated. Therefore this study examined an in vitro CMV superinfection of EBV latently infected cell lines (BJAB-B1 and P3HR-1 cells) and the effect on EBV reactivation. These B-cell lines were observed to be susceptible to a CMV superinfection and EBV reactivation occurs only in the cell lines superinfected with CMV. The observations in this study support the previous in vivo and in vitro findings by showing that potential interactions exist between CMV and EBV. Overall, these data suggest CMV may be a cofactor in EBV pathogenesis in the immunosuppressed patient.
CMV transcript in BJAB-B1 and P3HR-1 cells
CMV quantities of standards and superinfected BJAB-B1 cells.
Threshold Cycle (TC)
Starting Quantity (SQ)
5.00 × 105
5.00 × 103
5.00 × 101
4.07 × 100
1.34 × 10-1
1.79 × 10-1
2.96 × 10-1
3.14 × 10-1
CMV quantities of superinfected P3HR-1 cells.
Threshold Cycle (TC)
Starting Quantity (SQ)
5.00 × 105
5.00 × 103
5.00 × 101
1.98 × 100
9.01 × 10-1
2.17 × 101
CMV antigen in P3HR-1 and BJAB-B1 cells
Flow cytometry data of p52 antigen within BJAB-B1 cells.
CMV undergoes an abortive infection in BJAB-B1 cells
A CMV abortive infection was not determined for the P3HR-1 cells. In order to determine if CMV was undergoing an abortive or replicative infection, separate CMV superinfection experiments were performed. Cells were washed after 5 hours incubation with CMV and fresh media was added. The CMV infections were carried out to 10 days. Supernatants were taken immediately after washing to show absence of unattached CMV. Aliquots were taken at 24 and 48 hours for immunofluorescence analysis to confirm CMV infection (data not shown). After 10 days the cells were vortexed and supernatant was collected and placed into cultures of MRC-5 fibroblasts. MRC-5 infections were carried out to 10 days. No CPE was observed in any of the fibroblast infections, suggesting that an abortive infection was occurring in the BJAB-B1 cells.
EBV reactivation after CMV superinfections of BJAB-B1 and P3HR-1 cells
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
Amplification of the housekeeping gene G3PDH served as a control for RNA integrity. The product was analyzed by agarose (2%) gel electrophoresis and stained with ethidium bromide. This transcript was present at all time points among all experimental groups for both cell lines (data not shown).
This study has shown that the BJAB-B1 and P3HR-1 cell lines were susceptible to a CMV superinfection, and a low amount of infection was observed. Numerous studies have been able to show that PBMCs and B-cells in particular can have expression of viral transcript and/or antigen [35–41] however, other studies have been contradictory [40, 42] and therefore no consensus among the observations noted. Early studies have shown that in other B-cell lines, CMV DNA has been observed [43–45]. The MOI used in this study (20) indicates that there were 20 virus particles per BJAB-B1 or P3HR-1 cell. This high MOI would have seemed to ensure that enough CMV was present to superinfect the respective cell lines. However, despite the high MOI, the real-time PCR and immunofluorescent staining data from the BJAB-B1 and P3HR-1 cells show low amounts of infection present.
The concept of this study was to show evidence that CMV can superinfect these B-cell lines and may induce EBV reactivation by using a standardized CMV preparation. Infectivity differences have been observed between clinical isolates of CMV and laboratory adapted strains. The strain used in this study, AD169, and the Towne strains were both used to develop vaccines . Differences in infectivity have been observed between 2 of the same strains of CMV and this may be attributed to the deletion or mutation of certain tropism genes upon extensive serial propagation [50, 51]. Clinical isolates (wild-type CMV) can carry more than 220 genes, and some of these genes can be lost by deletion and/or rearrangement during laboratory passage . The AD169 strain used in this study has been passaged many times and because of these variations observed among the CMV strains, this may partly account for the low infectivity observed in the BJAB-B1 and P3HR-1 cells. Perhaps an increase in CMV infection in the cell lines could have been obtained with the use of a clinical isolate of CMV. Our laboratory is currently collecting clinical isolates of CMV for future superinfection experiments.
The first step in CMV infection is attachment to its cellular target; however, the receptors for CMV have not yet been delineated. Heparin sulfate and CD13 have been suggested to be involved in CMV attachment [52–54]. Heparin sulfate is a receptor present on many cell types, but CD13 is not expressed on B-cells. Even with these receptors being implicated as requirements for CMV adherence and penetration, the wide range of cellular tropism observed would suggest that additional receptors might be used.
The detection of CMV protein was performed to further show CMV infection in the cell lines used. The CMV p52 antigen is expressed in the early phase of infection and in the nuclei of infected cells. During a replicative infection, expression of this protein continues through to the late phase of infection . One function of the p52 protein is to aid in replication by binding to the viral DNA polymerase. The immunofluorescence data confirms the real-time PCR data showing that BJAB-B1 and P3HR-1 cells were susceptible to a CMV superinfection and a low amount of infection was observed. The p52 expression as shown in the flow cytometry data of the BJAB-B1 cells also indicate that a low amount of infection was observed. The numbers of p52 positive cells was also observed to decrease with respect to time, perhaps indicating an abortive infection may be occurring. No CPE was observed in any of the fibroblast superinfection studies indicating a lack of extracellular CMV infectious particles. We did not test for cell associated CMV in these experiments, so it is possible that virus emerging from the infected B-cell line may be bound to other cells in the culture. However, the fact that only a small percentage of the B-cells showed evidence of CMV infection along with the lack of virus in the supernatant supports the probability that the CMV infection of the BJAB-B1 cells represents an abortive infection. The data represented here support the work of others showing that CMV may undergo an abortive infection in B-cells rather than a productive one [35, 36, 46–48].
Regardless of whether viable CMV or UV-irradiated CMV is used, the virus still can attach to the host cell and cause the upregulation of cellular genes, including proto-oncogenes [55, 57–59]. It was observed in this study that the UV-irradiated CMV had no effect on BZLF1 transcript expression, suggesting that the effect observed in the superinfected BJAB-B1 and P3HR-1 cells was not attachment mediated and infectious CMV is at least required. At this point it has not been determined if CMV acts directly or indirectly to cause EBV reactivation. A direct effect would imply that a CMV transactivator is produced that could somehow cause the expression of or at least aid in the activation of the BZLF1 gene. Flamand et al. observed that HHV-6 (same subfamily as CMV) could cause the reactivation of EBV . The authors suggested that HHV-6 was having a direct effect on EBV reactivation because they were able to observe the presence of both viral antigens in the same cell. However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known. There may be some as yet unknown host cell gene or genes that are activated or upregulated in association with HHV-6 penetration and infection. Obviously the same uncertainties can be applied to the CMV superinfections of the BJAB-B1 and P3HR-1 cells.
The BZLF1 gene of EBV is an immediate early gene involved in the first step of EBV reactivation, and its activity is controlled at the transcriptional level [60–66], by protein-protein interactions [64–68], and phosphorylation [64, 69, 70]. Perhaps CMV may cause the activation of certain cellular kinases, which in turn may activate BZLF1 transcript expression. CMV has been shown to cause calcium flow and protein kinase C (PKC) activation that could then be involved in the early activation of transcription factors . Cellular levels of secondary messengers inositol 1,4,5-triphosphate and 1,2-diacylglycerol [71–73], as well as the MAP kinases (ERK1 and ERK2) [74, 75] are also known to be upregulated, which may have an effect on EBV reactivation. One study performed a DNA microarray analysis on CMV infected cells and observed an upregulation of 258 cellular mRNAs whose level changes were by a factor of 4 or more after the onset of viral replication . The functions of some of these genes still remains highly speculative, yet it gives an insight as to what potential roles these genes may play, particularly in EBV reactivation.
The CMV transcript expression in BJAB-B1 cells was observed beginning at 24 hours and was expressed through to 168 hours. The BZLF1 transcript was observed beginning at 48 hours and expressed though 96 hours. There was a greater amount of CMV MIE transcript present compared to the BZLF1 transcript in the BJAB-B1 cells. BZLF1 protein expression was observed only at 168 hours post CMV superinfection. CMV p52 protein expression was observed through 168 hours post superinfection (immunofluorescence and flow cytometry data) and p52 positive cells peaked at 72 hours (flow cytometry). Among the P3HR-1 cells, the CMV transcript was also expressed from 96 hours to 168 hours; however, the viral load increases with respect to time as opposed to the BJAB-B1 cells. During the earlier time points (24, 48, and 72 hours), the sample curves have not yet crossed the threshold and therefore were not included in the program's final quantitative analysis. The BZLF1 transcript in the superinfected P3HR-1 cells shows presence at 24 hours, decreases at subsequent time points and finally peaks at 168 hours. Differences in the CMV and BZLF1 transcript expression between the BJAB-B1 and P3HR-1 cells may be attributed to the fact that these are different cell lines, despite the presence of EBV. The kinetic expression of both viral transcripts and proteins in the respective cell lines would seem to suggest that CMV may be having an indirect effect on EBV reactivation through the participation of cellular factors.
Despite the low infectivity of the BJAB-B1 and P3HR-1 cells by CMV, EBV reactivation was observed in the experimental groups superinfected with CMV. The cell lines that were exposed to UV-irradiated CMV had no indication of BZLF1 transcript or protein suggesting that the effect on EBV reactivation was not attachment mediated and that infectious CMV was required. In vivo, it would be difficult to pinpoint one specific factor to cause the switch from latency to lytic infection. However, in vitro, it was most interesting to observe EBV reactivation only in the cell lines that were superinfected with CMV.
A CMV infection, in vivo, can contribute to the net immunosuppressive status of the immunocompromised patient . A CMV infection can result in the production of certain immune effector proteins (cytokines and chemokines) that may affect latency in the EBV infected B-cells . The production of these cytokines and chemokines from a CMV superinfected BJAB-B1 or P3HR-1 cell may affect neighboring cells and therefore cause EBV reactivation, implying that CMV could be having an indirect effect on EBV latency.
Because CMV infection and disease is such an important concern among the immunosuppressed patient populations (transplant and HIV infected individuals), its involvement in the reactivation of EBV must be considered. This report has shown that BJAB-B1 and P3HR-1 cells, both latently infected with EBV, were susceptible to a CMV superinfection and only in the experimental groups that were superinfected with CMV were there any indication of EBV reactivation. These data support the clinical studies showing an in vivo relationship between a CMV active infection and EBV reactivation. Although it would be very difficult to prove that a CMV infection is the cause of EBV reactivation in clinical situations due to the gamut of factors that are involved, the fact that EBV reactivation was observed after in vitro CMV superinfections supports this role. Inducers of EBV replication are of importance because of the serious complications that are associated with recurrent EBV infections, particularly in immunosuppressed individuals. Since a majority of the population is seropositive for CMV, reactivation of CMV in immunosuppressed patients may further accentuate the reactivation of EBV therefore contributing to the proliferation of EBV infected B-cells. The results in this project suggest that CMV may contribute as a co-factor in EBV pathogenesis. More detailed molecular studies are needed to examine the direct and/or indirect effects CMV may have on EBV.
Cells and virus
P3HR-1 (ATCC) and BJAB-B1 cells (generously donated by Dr. George Miller) are EBV latently infected B-cells kept in RPMI 1640 medium (supplemented with 10% FBS and an antibiotic-mycotic solution) (Gibco, Invitrogen Corp., Carlsbad, CA). The AD169 laboratory strain of CMV was from the clinical virology laboratory (Tampa General Hospital, Tampa, FL), and used for the superinfections. CMV was grown and harvested from MRC-5 fibroblast cultures (Biowhittaker, Walkersville, MD) and concentrated by ultra-centrifugation (28000 g for 60 minutes at 4°C). The CMV titer was determined using the shell vial assay. Briefly, this is an immunofluorescence assay in which 1:10 dilutions of the virus were prepared in shell vials and incubated at 37°C overnight. The MRC-5 cells in the shell vials were fixed and permeabilized for 15 minutes in methanol:acetone (1:1) and then washed in PBS (Bartels Inc., Intracel Corp., Frederick, MD, reconstituted in 1 liter of Millipore water, pH 7.0–7.6). The cells were stained with a FITC labelled antibody directed against the major immediate early antigen (MIE) (Chemicon, Temecula, CA) and visualized using a fluorescent microscope. Each green (positive) cell was counted as one viral particle.
CMV superinfection of the BJAB-B1 and P3HR-1 cells
500,000 cells were counted using the Cell-DYN 4000 (Abbott Systems, Abbott Park, IL) and placed in a 24-well culture plate with RPMI 1640 medium. The P3HR-1 and BJAB-B1 cells were infected at a multiplicity of infection (MOI) of 20 and were either uninfected, infected, or exposed to UV-irradiated virus. CMV was exposed to UVC light for 2 hours in our biological safety cabinet. The experiments were carried out for 7 days and samples were taken at 24, 48, 72, 96, and 168 hours. Time points for the P3HR-1 cells were the same except for an additional time point at 120 hours. At each time point, cells were analyzed by immunofluorescence and real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The P3HR-1 cells were not subjected to flow cytometric analysis. Superinfections were repeated three times and data shown are representative experiments.
MRC-5 fibroblast infection of supernatants from CMV superinfections
Separate superinfection experiments of the BJAB-B1 cells were set up and were incubated with CMV for 5 hours to allow for viral attachment. The cells were then washed to remove any unattached virus and fresh medium was added. The CMV superinfections were carried out to 10 days. The cultures were vortexed, supernatant was collected, and added to cultures of MRC-5 fibroblasts. Supernatant fluid was collected immediately after infection and washing to establish that any unattached CMV was not present. MRC-5 fibroblasts were examined for CPE.
Immunofluorescent staining for p52 (CMV) and BZLF1 (EBV)
Aliquots of 100 μl (approximately 50,000 cells) from each experimental group were subjected to a cytospin and fixed and permeabilized similarly to the shell vial assay. The anti-p52 and anti-BZLF1 antibodies (Dako Corporation, Carpinteria, CA) were prepared according to package inserts. Evan's Blue was added to the final p52 solution. The p52 antibody was directly labelled with FITC (fluorescein isothiocyanate) and did not require a secondary antibody step. The BZLF1 antibody is unlabelled and required a secondary goat anti-mouse antibody labelled with FITC. The secondary antibody was diluted 1:200 in PBS and Evan's Blue was added. The primary and secondary antibodies were incubated in a humidified chamber at 37°C for 30 minutes. The slides were washed in PBS after each incubation step, prepared with mounting media, and visualized under a fluorescent microscope.
Flow cytometry of p52 antigen
Aliquots of 300 μl (approximately 150,000 cells) were placed in 5-ml Falcon tubes and washed in PBS. The cells were fixed and permeabilized with pre-made solutions from Caltag Laboratories (Burlingame, CA) (Fix & Perm) according to kit instructions. During the permeabilization step, FITC-labelled antibody (p52) was added at a 1:5 dilution. Cells were washed in PBS and then 750 μl of paraformaldehyde was added and read on the FACScalibur flow cytometer (Becton Dickinson, Los Angeles, CA). Fluorescence parameters were set with regards to infected and uninfected samples. CMV infected and uninfected MRC-5 fibroblasts were used as positive controls for viable CMV and antibody staining. 10,000 BJAB-B1 cells were first separated according to size and granularity (forward vs. side scatter) on a dot plot. Viable cells were then selected and gated for further analysis on a histogram for FL1 (FITC, p52 antigen) versus cell counts. The final histogram analyses involved subtracting background of the corresponding mock-infected cells from the BJAB-B1 cells superinfected with CMV or UV-irradiated CMV. Analysis was performed using the CellQuest software (Becton Dickinson, Los Angeles, CA). The P3HR-1 cells were not analysed by flow cytometry.
RNA extraction and isolation
The nucleic acid isolation was performed on an automated extractor from the Organon Tekinika Corporation (Boxtel, Netherlands) and the extractions were performed according to kit instructions modified from the method by Boom et al. . All reagents used for extractions were from the company. Aliquots of 400 μl (approximately 200,000 cells) were used per experimental time point. The final result was approximately 50 μl of nucleic acid in elution buffer. The nucleic acid samples were then subjected to DNase treatment and RNA clean up with Ambion's (Austin, TX) DNA-free kit following their provided protocol.
Using Ribogreen dye and RNA quantitation standards from Molecular Probes (Eugene, OR), the amount of RNA in the experimental samples were calculated. Briefly, an aliquot of the RNA samples were diluted 1:100 in TE buffer. RNA standards were prepared (4000, 2000, 1000, 500, 250, and 125 ng). The Ribogreen dye was diluted 1:200 in TE buffer and 20 μl of the diluted RNA (standard or sample) was mixed with 20 μl of the diluted Ribogreen dye. Samples and standards were placed in a microtiter plate and read on the CytoFluor reader from Applied Biosystems (Foster City, CA) (excitation 485 nm/20 nm and emission 530 nm/25 nm). The standard curve and sample quantitations were determined using an Excel spreadsheet.
RNA for cDNA production was performed using Promega's (Madison, WI) random hexamers, RNAsin, RT buffer, and RT enzyme. For each sample, the RNA (2 μg) was initially incubated with the random hexamers (0.5 μg) and enough PCR grade water to bring the volume up to 20 μl. Incubation of the RNA and random hexamers was performed at 95°C for 5 minutes and then held at 4°C. The RT mix included 5.6 μl of 5X RT buffer, 0.02 mM of dNTPs (with dTTP, not dUTP, Perkin Elmer, Foster City, CA), 14.22 units of AMV RT enzyme, and 20 units of RNAsin per reaction. A total of 9.68 μl of the RT mix was added to the RNA samples (with the random hexamers) and then subjected to RT cycle conditions (42°C for 45 minutes, 95°C for 5 minutes and a 4°C hold). All incubations were done on BioRad's iCycler (Richmond, CA). Mock RTs were set up in which PCR grade water was substituted for the RT enzyme as a check for DNA contamination.
The PCR mix per reaction included 10 μl SYBR Green buffer, 1.5 mM MgCl2, 1 μM dNTP mix (with dUTP), 0.5 μl CMV primer mix, 2.5 units AmpliTaq gold, 0.05 units of uracil-N-glycosylase (UNG, Epicentre, Madison, WI) that had been diluted 1:10 in UNG buffer, and molecular grade water to bring the volume up to 45 μl with the addition of 5 μl of cDNA or standard. The PCR reagents were obtained from Perkin Elmer. The CMV primers, from Synthetic Genetics, Inc. (San Diego, CA), amplify the MIE gene. The BZLF1 primers recognize only mRNA and the sequences are 5'-TTCCACAGCCTGCACCAGTG-3' and 5'-GGCAGCAGCCACCTCACGGT-3' . Primers were generated by Sigma Genosys (The Woodlands, TX). The CMV PCR was quantitative and the BZLF1 PCR was qualitative. The PCR consisted of 2 pre-incubation steps, 37°C/15 minutes and 95°C/10 minutes (for UNG activation and UNG denaturation/Taq activation). The cycles for PCR were 95°C/30 seconds, 55°C/30 seconds, and 72°C/30 seconds for 35 cycles. CMV DNA copy standards (Synthetic Genetics, Inc.) were used to set up a standard curve. Standards were 500000, 5000, and 50 CMV DNA copies. Dilutions were set up using PCR grade water. The software (Bio-Rad, Richmond, CA) calculated the standard curve as well as determined the amount of CMV DNA in the superinfected samples. Agarose (2%) gel electrophoresis was performed in order to determine the specificity of the PCR reactions in the BJAB-B1 cells only. Primers and positive control for the glyceraldehyde-3-phosphate dehydrogenase housekeeping gene were from Clontech (BD Biosciences Clontech, Palo Alto, CA). PCR recipe and conditions were run according to the included protocol. G3PDH transcripts from both cell lines were analyzed on a 2% agarose gel only.
Real-time PCR analysis
The instrument camera took numerous fluorescence readings during the annealing stages and displayed the average reading for that particular cycle. At the end of the PCR cycling, the base line fluorescence was calculated and all the samples were normalized to zero. The threshold level (CT) was set at a point when the standards or positive control were in its respective exponential phase of amplification. The CT value is the cycle number in which a sample's fluorescence crosses the set threshold level, and therefore is called positive. During quantitative analysis, the standard curve was calculated and the sample concentrations were derived from the curve. All calculations were performed with the included software.
We thank Dr. Tammy Santana for helping us to obtain the BJAB-B1 cells from Dr. George Miller. We also thank Drs. Steven Specter, Peter Medveczky, and Susan Pross for their critique of the manuscript.
- Rosenthal KS: Human Herpesviruses. In: Medical Microbiology. Edited by: Farrell R. 1994, St. Louis, Missouri, Mosby-Year Books, Inc, 571-594.Google Scholar
- Steven NM: Epstein-Barr Virus Infection in vivo. Rev Med Virol. 1997, 7: 97-106. 10.1002/(SICI)1099-1654(199707)7:2<97::AID-RMV190>3.0.CO;2-M.View ArticlePubMedGoogle Scholar
- Magrath IT, Pizzo PA, Novikovs L, Levine AS: Enhancement of Epstein-Barr Virus Replication in Producer Cell Lines by a Combination Of Low Temperature and Corticosteroids. Virology. 1979, 97: 477-481. 10.1016/0042-6822(79)90360-X.View ArticlePubMedGoogle Scholar
- Bauer G: Induction of Epstein-Barr Virus Early Antigens by Corticosteroids: Inhibition by TPA and Retinoic Acid. Int J Cancer. 1983, 31: 291-295.View ArticlePubMedGoogle Scholar
- Schuster C, Chasserot-Golaz S, Beck G: Activation of Epstein-Barr Virus promoters by a Growth Factor and a Glucocorticoid. FEBS Lett. 1991, 284: 82-86. 10.1016/0014-5793(91)80767-W.View ArticlePubMedGoogle Scholar
- Glaser R, Kutz LA, MacCallum RC, Malarkey WB: Hormonal Modulation of Epstein-Barr Virus Replication. Neuroendocrinology. 1995, 62: 356-361.View ArticlePubMedGoogle Scholar
- Sarid O, Anson O, Yaari A, Margalith M: Epstein-Barr Virus Specific Salivary Antibodies as Related to Stress Caused by Examinations. J Med Virol. 2001, 64: 149-156. 10.1002/jmv.1030.View ArticlePubMedGoogle Scholar
- Cavert W: Viral Infections in Human Immunodeficiency Virus Disease. Med Clin North Am. 1997, 81: 411-426.View ArticlePubMedGoogle Scholar
- Fishman JA, Rubin RH: Infection in Organ-Transplant Recipients. New Engl J Med. 1998, 338: 1741-1751. 10.1056/NEJM199806113382407.View ArticlePubMedGoogle Scholar
- Tolkoff-Rubin NE, Rubin RH: Viral Infections in Organ Transplantation. Transplant Proc. 1998, 30: 2060-2063. 10.1016/S0041-1345(98)00541-7.View ArticlePubMedGoogle Scholar
- van Son WJ, de Maar EF, van der Bij W, van der Berg AP, Vershuuren EAM, Hauw The T: Overcoming the Problem of Cytomegalovirus Infection After Organ Transplantation: Calling for Heracles?. Intervirol. 1999, 42: 285-290. 10.1159/000053962.View ArticleGoogle Scholar
- Snydman DR: Epidemiology of Infections After Solid-Organ Transplantation. Clin Infect Dis. 2001, 33: S5-S8. 10.1086/320897.View ArticlePubMedGoogle Scholar
- van der Bij W, Speich R: Management of Cytomegalovirus Infection and Disease After Solid-Organ Transplantation. Clin Infect Dis. 2001, 33: S32-S37. 10.1086/320902.View ArticlePubMedGoogle Scholar
- Fiala M, Payne JE, Berne TV, Moore TC, Henle W, Montgomeriez JZ, Chatterjee SN, Guze LB: Epidemiology of Cytomegalovirus Infection After Transplantation and Immunosuppression. J Infect Dis. 1975, 132: 421-433.View ArticlePubMedGoogle Scholar
- Hibberd PL, Snydman DR: Cytomegalovirus Infection in Organ Transplant Recipients. Infect Dis Clin North Am. 1995, 9: 863-877.PubMedGoogle Scholar
- So S: CMV and EBV-PTLD After Liver Transplantation. Transplant Proc. 2001, 33: 1317-1319. 10.1016/S0041-1345(00)02815-3.View ArticlePubMedGoogle Scholar
- Zaia JA, Forman SJ: Cytomegalovirus Infection in the Bone Marrow Transplant Recipient. Infect Dis Clin North Am. 1995, 9: 879-900.PubMedGoogle Scholar
- Walling DM, Clark NM, Markovitz DM, Frank TS, Braun DK, Eisenberg E, Krutchkoff DJ, Felix DH, Raab-Traub N: Epstein-Barr Virus Coinfection and Recombination in Non-human Immunodeficiency Virus-Associated Oral Hairy Leukoplakia. J Infect Dis. 1995, 171: 1122-1130.View ArticlePubMedGoogle Scholar
- Okano M, Gross TG: A Review of Epstein-Barr Virus Infection in Patients with Immunodeficiency Disorders. Am J Med Sci. 2000, 319: 392-396. 10.1097/00000441-200006000-00009.View ArticlePubMedGoogle Scholar
- Diaz-Mitoma F, Ruiz A, Flowerdew G, Houston S, Romanowski B, Kovithavongs T, Preiksaitis J, Tyrrell DL: High Levels of Epstein-Barr Virus in the Oropharynx: A Predictor of Disease Progression in Human Immunodeficiency Virus Infection. J Med Virol. 1990, 31: 69-75.View ArticlePubMedGoogle Scholar
- Birx DL, Redfield RR, Tosato G: Defective Regulation of Epstein-Barr Virus Infection in Patients With Acquired Immunedeficiency Syndrome (AIDS) or AIDS-related Disorders. N Engl J Med. 1986, 314: 874-879.View ArticlePubMedGoogle Scholar
- Basgoz N, Preiksaitis JK: Post-Transplant Lymphoproliferative Disorder. Infect Dis Clin North Am. 1995, 9: 901-923.PubMedGoogle Scholar
- Hopwood P, Crawford DH: The Role of EBV in Post-Transplant Malignancies: A Review. J Clin Pathol. 2000, 53: 248-254. 10.1136/jcp.53.4.248.PubMed CentralView ArticlePubMedGoogle Scholar
- Preiksaitis JK, Keay S: Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. Clin Infect Dis. 2001, 33: S38-S46. 10.1086/320903.View ArticlePubMedGoogle Scholar
- Horvat RT, Wood C, Balachandran N: Transactivation of Human Immunodeficiency Virus Promoter by Human Herpesvirus-6. J Virol. 1989, 63: 970-973.PubMed CentralPubMedGoogle Scholar
- Lusso P, Gallo RC: Human Herpesvirus 6 in AIDS. Immunol Today. 1995, 16: 67-71. 10.1016/0167-5699(95)80090-5.View ArticlePubMedGoogle Scholar
- Ensoli B, Lusso P, Schachter F, Josephs SF, Rappaport J, Negro F, Gallo RC, Wong-Staal F: Human Herpes Virus-6 Increases HIV-1 Expression in Co-Infected T Cells via Nuclear Factors Binding to the HIV-1 Enhancer. EMBO J. 1989, 8: 3019-3027.PubMed CentralPubMedGoogle Scholar
- Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, Gallo RC: Induction of CD4 and Susceptibility to HIV-1 Infection in CD8+ T Lymphocytes by Human Herpesvirus 6. Nature. 1991, 349: 533-535. 10.1038/349533a0.View ArticlePubMedGoogle Scholar
- Lusso P, Malnati MS, Garzino-Demo A, Crowley RW, Long EO, Gallo RC: Infection of Natural Killer Cells by Human Herpesvirus 6. Nature. 1993, 362: 458-462. 10.1038/362458a0.View ArticlePubMedGoogle Scholar
- Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M: Posttransplant Lymphoproliferative Disease in Primary Epstein-Barr Virus Infection after Liver Transplantation: The Role of Cytomegalovirus Disease. J Infect Dis. 1997, 176: 1462-1467.View ArticlePubMedGoogle Scholar
- Aalto SM, Linnavuori K, Peltola H, Vurori E, Weissbrich B, Schubert J, Hedman L, Hedman K: Immunoreactivation of Epstein-Barr Virus Due to Cytomegalovirus Primary Infection. J Med Virol. 1998, 56: 186-191. 10.1002/(SICI)1096-9071(199811)56:3<186::AID-JMV2>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Hornef MW, Bein G, Fricke L, Steinhoff J, Wagner HJ, Hinderer W, Sonneborn HH, Kirchner H: Coincidence of Epstein-Barr Virus Reactivation, Cytomegalovirus Infection, and Rejection Episodes in Renal Transplant Recipients. Transplantation. 1995, 60: 474-480.View ArticlePubMedGoogle Scholar
- Flamand L, Stefanescu I, Ablashi DV, Menezes J: Activation of the Epstein-Barr Virus Replicative Cycle by Human Herpesvirus 6. J Virol. 1993, 67: 6768-6777.PubMed CentralPubMedGoogle Scholar
- Vieira J, O'Hearn P, Kimball L, Chandran B, Corey L: Activation of Kaposi's Sarcoma-Associated herpesvirus (Human Herpesvirus 8) Lytic Replication by Human Cytomegalovirus. J Virol. 2001, 75: 1378-1386. 10.1128/JVI.75.3.1378-1386.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Rice GPA, Schrier RD, Oldstone MBA: Cytomegalovirus Infects Human Lymphocytes and Monocytes: Virus Expression is Restricted to Immediate-Early Gene Products. Proc Natl Acad Sci USA. 1984, 81: 6134-6138.PubMed CentralView ArticlePubMedGoogle Scholar
- Braun RW, Reiser HC: Replication of Human Cytomegalovirus in Human Peripheral Blood T Cells. J Virol. 1986, 60: 29-36.PubMed CentralPubMedGoogle Scholar
- Gerna G, Zipeto D, Percivalle E, Parea M, Revello MG, maccario R, Peri G, Milanesi G: Human Cytomegalovirus Infection of the Major Leukocyte Subpopulations and Evidence for Initial Viral Replication in Polymorphonuclear Leukocytes From Viremic Patients. J Infect Dis. 1992, 166: 1236-1244.View ArticlePubMedGoogle Scholar
- Bruggeman CA: Cytomegalovirus and Latency: An Overview. Virchow Arch B Cell Pathol Incl Mol Pathol. 1993, 64: 325-333.View ArticleGoogle Scholar
- Soderberg C, Larsson S, Bergstedt-Lindqvist S, Moller E: Identification of Blood Mononuclear Cells Permissive of Cytomegalovirus Infection In Vitro. Transplant Proc. 1993, 25: 1416-1418.PubMedGoogle Scholar
- Soderberg C, Larsson S, bergstedt-Lindqvist S, Moller E: Definition of a Subset of Human Peripheral Blood Mononuclear Cells That Are Permissive to human Cytomegalovirus Infection. J Virol. 1993, 67: 3166-3175.PubMed CentralPubMedGoogle Scholar
- Hassan-Walker AF, Mattes FM, Griffiths PD, Emery VC: Quanitity of Cytomegalovirus DNA in Different Leukocyte Populations During Active Infection In Vivo and The Presence of gB and UL18 Transcripts. J Med Virol. 2001, 64: 283-289. 10.1002/jmv.1048.View ArticlePubMedGoogle Scholar
- Schrier RD, Nelson JA, Oldstone MBA: Detection of Human Cytomegalovirus in Peripheral Blood Lymphocytes in a Natural Infection. Science. 1985, 230: 1048-1051.View ArticlePubMedGoogle Scholar
- Joncas JH, Menezes J, Huang ES: Persistence of CMV Genome in Lymphoid Cells After Congenital Infection. Nature. 1975, 258: 432-434.View ArticlePubMedGoogle Scholar
- St. Jeor S, Weisser A: Persistence of Cytomegalovirus in Human Lymphoblasts and Peripheral Leukocyte Cultures. Infect Immun. 1977, 15: 402-409.PubMed CentralPubMedGoogle Scholar
- Tocci MJ, St. Jeor SC: Susceptibility of Lymphoblastoid Cells to Infection With Human Cytomegalovirus. Infect Immun. 1979, 23: 418-423.PubMed CentralPubMedGoogle Scholar
- Grefte A, Harmsen MC, van der Giessen M, Knollema S, van Son WJ, Hauw The T: Presence of Human Cytomegalovirus (HCMV) Immediate Early mRNA but not ppUL83 (lower matrix protein pp65) mRNA in Polymorphonuclear and Mononuclear Leukocytes During Active HCMV Infection. J Gen Virol. 1994, 75: 1989-1998.View ArticlePubMedGoogle Scholar
- Gerna G, Percivalle E, Baldanti F, Sozzani S, lanzarini P, Genini E, Lilleri D, Revello MG: Human Cytomegalovirus Replicates Abortively in Polymorphonuclear Leukocytes After Transfer From Infected Endothelial Cells via Transient Microfusion Events. J Virol. 2000, 74: 5629-5638. 10.1128/JVI.74.12.5629-5638.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S, Gerna G: In Vitro Generation of Human Cytomegalovirus pp65 Antigenemia, Viremia, and LeukoDNAemia. J Clin Invest. 1998, 101: 2686-2692.PubMed CentralView ArticlePubMedGoogle Scholar
- Cha T, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR: Human Cytomegalovirus Clinical Isolates Carry at Least 19 Genes Not Found in Laboratory Strains. J Virol. 1996, 70: 78-83.PubMed CentralPubMedGoogle Scholar
- Brown JM, Kaneshima H, Mocarski ES: Dramatic Interstrain Differences in the Replication of Human Cytomegalovirus in SCID-hu Mice. J Infect Dis. 1995, 171: 1599-1603.View ArticlePubMedGoogle Scholar
- Quinnan GV, Delery M, Rook AH, Frederick WR, Epstein JS, Manischewitz JF, Jackson L, Ramsey KM, Mittal K, Plotkin SA: Comparative Virulence and Immunogenicity of the Towne Strain and a Nonattenuated Strain of Cytomegalovirus. Ann Intern Med. 1984, 101: 478-483.View ArticlePubMedGoogle Scholar
- Neyts J, Snoeck R, Schols D, Balzarini J, Esko JD, Van Schepdael A, DeClerq E: Sulfated Polymers Inihibit the Interaction of Human Cytomegalovirus With Cell Surface Heparin Sulfate. Virology. 1992, 189: 48-58. 10.1016/0042-6822(92)90680-N.View ArticlePubMedGoogle Scholar
- Compton T, Nowlin DM, Cooper NR: Initiation of Human Cytomegalovirus Infection Requires Initial Interaction With Cell Surface Heparin Sulfate. Virology. 1993, 193: 834-841. 10.1006/viro.1993.1192.View ArticlePubMedGoogle Scholar
- Larsson S, Soderberg-Naucler C, Moller E: Productive Cytomegalovirus (CMV) Infection Exclusively in CD13-Positive Peripheral Blood Mononuclear Cells From CMV-Infected Individuals: Implications for Prevention of CMV Transmission. Transplantation. 1998, 65: 411-415. 10.1097/00007890-199802150-00021.View ArticlePubMedGoogle Scholar
- Boldogh I, AbuBakar S, Deng CZ, Albrecht T: Transcriptional Activation of Cellular Oncogenes fos, jun, and myc by Human Cytomegalovirus. J Virol. 1991, 65: 1568-1571.PubMed CentralPubMedGoogle Scholar
- Ripalti A, Boccuni MC, Campanini F, Landini MP: Cytomegalovirus-Mediated Induction of Antisense mRNA Expression to UL44 Inhibits Virus Replication in an Astrocytoma Cell Line: Identification of an Essential Gene. J Virol. 1995, 69: 2047-2057.PubMed CentralPubMedGoogle Scholar
- Boldogh IS, AbuBakar S, Fons MP, Deng CZ, Albrecht T: Activation of Cellular Oncogenes by Clinical Isolates and Laboratory Strains of Human Cytomegalovirus. J Med Virol. 1991, 34: 241-247.View ArticlePubMedGoogle Scholar
- Boldogh I, AbuBakar S, Millinoff D, Deng CZ, Albrecht T: Cellular Oncogene Activation by Human Cytomegalovirus. Lack of Correlation With Virus Infectivity and Immediate Early Gene Expression. Arch Virol. 1991, 118: 163-177. 10.1007/BF01314027.View ArticlePubMedGoogle Scholar
- Doniger J, Muralidhar S, Rosenthal LJ: Human Cytomegalovirus and Human Herpesvirus-6 Genes That Transform and Transactivate. Clin Micro Rev. 1999, 12: 367-382.PubMed CentralPubMedGoogle Scholar
- Takada K, Shimzu N, Sakuma S, Ono Y: trans Activation of the Latent Epstein-Barr Virus (EBV) Genome After transfection of the EBV DNA Fragment. J Virol. 1986, 57: 1016-1022.PubMed CentralPubMedGoogle Scholar
- Countryman J, Jenson H, Seibl R, Wolf H, Miller G: Polymorphic Proteins Encoded Within the BZLF1 of Defective and Standard Epstein-Barr Viruses Disrupt Latency. J Virol. 1987, 61: 3672-3679.PubMed CentralPubMedGoogle Scholar
- Grogan E, Jenson H, Countryman J, Heston L, Gradoville L, Miller G: Transfection of a Rearranged Viral DNA Fragment, Wzhet, Stably Converts Latent Epstein-Barr Viral Infection to Productive Infection in Lymphoid Cells. Proc Natl Acad Sci USA. 1987, 84: 1332-1336.PubMed CentralView ArticlePubMedGoogle Scholar
- Kenney S, Kamine J, Hollet-Guthrie E, Lin J, Mar EC, Pagano J: The Epstein-Barr Virus (EBV) BZLF1 Immediate-Early Gene Product Differentially Affects Latent Versus Productive EBV Promoters. J Virol. 1989, 63: 1729-1736.PubMed CentralPubMedGoogle Scholar
- Speck SH, Chatila T, Flemington E: Reactivation of Epstein-Barr Virus: Regulation and Function of The BZLF1 Gene. Trends Microbiol. 1997, 5: 399-405. 10.1016/S0966-842X(97)01129-3.View ArticlePubMedGoogle Scholar
- Chang L, Liu S: Activation of the BRLF1 Promoter and Lytic Cycle of Epstein-Barr Virus by Histone Acetylation. Nucleic Acids Res. 2000, 28: 3918-3925. 10.1093/nar/28.20.3918.PubMed CentralView ArticlePubMedGoogle Scholar
- Jenkins PJ, Binne UK, Farrell PJ: Histone Acetylation and Reactivation of Epstein-Barr Virus From Latency. J Virol. 2000, 74: 710-720. 10.1128/JVI.74.2.710-720.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Adamson AL, Kenney S: The Epstein-Barr Virus BZLF1 Protein Interacts Physically and Functionally With The Histone Acetylase CREB-Binding Protein. J Virol. 1999, 73: 6551-6558.PubMed CentralPubMedGoogle Scholar
- Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I: Transforming Growth Factor Beta 1 Stimulates Expression of the Esptein-Barr Virus BZLF1 Immediate-Early Gene Product ZEBRA by an Indirect Mechanism Which Requires the MAPK Kinase Pathway. J Virol. 2000, 74: 5810-5818. 10.1128/JVI.74.13.5810-5818.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Daibata M, Humphreys RE, Sairenji T: Phosphorylation of the Epstein-Barr Virus BZLF1 Immediate-Early Gene Product ZEBRA. Virology. 1992, 188: 916-920. 10.1016/0042-6822(92)90553-2.View ArticlePubMedGoogle Scholar
- Borras AM, Strominger JL, Speck SH: Characterization of the ZI Domains in the Epstein-Barr Virus BZLF1 Gene Promoter: Role in Phorbol Ester Induction. J Virol. 1996, 70: 3894-3901.PubMed CentralPubMedGoogle Scholar
- Boldogh I, Fons MP, Albrecht T: Increased Levels of Sequence Specific DNA-Binding Proteins in Human Cytomegalovirus-Infected Cells. Biochem Biophys Res Commun. 1993, 197: 1505-1510. 10.1006/bbrc.1993.2647.View ArticlePubMedGoogle Scholar
- Valyi-Nagy T, Bandi Z, Boldogh I, Albrecht T: Hydrolysis of Inositol Lipids: An Early Signal of Human Cytomegalovirus Infection. Arch Virol. 1988, 101: 199-207. 10.1007/BF01311001.View ArticlePubMedGoogle Scholar
- Cinatl J, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW: Modulatory Effects of Human Cytomegalovirus Infection on Malignant Properties of Cancer Cells. Intervirology. 1996, 39: 259-269.PubMedGoogle Scholar
- Rodems SM, Spector DH: Extracellular Signal-Regulated Kinase Activity is Sustained Early During Human Cytomegalovirus Infection. J Virol. 1998, 72: 9173-9180.PubMed CentralPubMedGoogle Scholar
- Johnson RA, Ma XL, Yurochko AD, Huang ES: The Role of MKK1/2 Kinase Activity in Human Cytomegalovirus Infection. J Gen Virol. 2001, 82: 493-497.View ArticlePubMedGoogle Scholar
- Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T: Cellular Gene Expression Altered by Human Cytomegalovirus: Global Monitoring With Oligonucleotide Arrays. Proc Natl Acad Sci USA. 1998, 95: 14470-14475. 10.1073/pnas.95.24.14470.PubMed CentralView ArticlePubMedGoogle Scholar
- Mogensen TH, Paludan SR: Molecular Pathways in Virus-Induced Cytokine Production. Microbiol Mol Biol Rev. 2001, 65: 131-150. 10.1128/MMBR.65.1.131-150.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J: Rapid and Simple Method for Purification of Nucleic Acids. J Clin Microbiol. 1990, 28: 495-503.PubMed CentralPubMedGoogle Scholar
- Tierney RJ, Steven N, Young LS, Rickinson AB: Epstein-Barr Virus Latency in Blood Mononuclear Cells: Analysis of Viral Gene Transcription During Primary Infection and in the Carrier State. J Virol. 1994, 68: 7374-7385.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.